Navigation Links
HeartWare Appoints Timothy J. Barberich to Board of Directors
Date:4/30/2008

Founder, Former CEO of Sepracor Inc. (Nasdaq: SEPR)

FRAMINGHAM, Mass. and SYDNEY, Australia, April 30 /PRNewswire-FirstCall/ -- HeartWare Limited (ASX: HTW) today announced that veteran healthcare executive Timothy J. Barberich has been appointed to its Board as a non- executive director, effective immediately.

Barberich, 60, is the founder and former president, chief executive officer and chairman of Marlborough, MA-based Sepracor Inc., a publicly traded pharmaceutical company with 2007 revenues of US$1.2 billion that specializes in developing drugs for respiratory and central nervous system disorders. Barberich founded Sepracor in 1984 and was president and chief executive officer through 1999 when he also became chairman. He retired in May 2007 but remains Sepracor's chairman.

Barberich also serves on the boards of BioSphere Medical, Gemin X Biotechnologies, Resolyx Pharmaceuticals and serves on the Board of Trustees of Boston Medical Center.

"Tim is an extraordinarily experienced healthcare executive. His record of creating, leading and growing private and publicly traded companies in both the pharmaceutical and medical device arena is remarkable," said HeartWare Chairman Mr. Rob Thomas. "Tim's extensive operational, financial and corporate experience will be of great value to HeartWare as we advance our unique HeartWare(R) LVAD System towards an international market launch and the start of our US clinical trial later this year."

Prior to founding Sepracor, Barberich spent 10 years as a senior executive at Bedford, MA-based Millipore Corporation, a company that provides separations products to the life science research, pharmaceutical, biotechnology and electronic markets.

Barberich is a graduate of Kings College. He holds a BS degree in Chemistry.

With the addition of Mr. Barberich, the HeartWare Board of Directors now totals 7 members.

About HeartWare

HeartWare develops and manufactures miniaturized implantable heart pumps, or Left Ventricular Assist Devices (LVADs), designed to treat patients suffering from advanced heart failure. The Company is developing the industry's smallest and least invasive pumps, which it believes will be the key to unlocking the potential of a large and underserved market. The HeartWare(R) LVAD is a full-output pump designed to be implanted in the chest, avoiding the abdominal surgery generally required to implant competing devices. The device is currently the subject of an international clinical trial involving five investigational centres in Europe and Australia. A clinical trial in the U.S. is expected to begin in the first half of 2008.

For further information:

http://www.heartware.com.au US Investor Relations

Howard Leibman Matt Clawson

Director Corporate Development Partner

HeartWare Limited Allen & Caron, Inc.

Email. howard.leibman@heartware.com.au Email. matt@allencaron.com

Tel. +61 2 9238 2064 Tel. +1 949 474 4300


'/>"/>
SOURCE HeartWare Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from ... believe could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving ... to read it now. , Biomarkers are components in the blood, tissue ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):